0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Remote symptom monitoring with patient-reported outcome measures in outpatients with chronic kidney disease (PROKID): a multicentre randomised controlled non-inferiority study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Background

          The increasing incidence of chronic kidney disease (CKD) is straining the capacity of outpatient clinics. Remote healthcare delivery might improve CKD follow-up compared with conventional face-to-face follow-up. Patient-reported outcomes (PROs) are used to empower remote follow-up and patient engagement. The consequences of shifting from face-to-face follow-up to remote outpatient follow-up on kidney function, health resource utilisation and quality of life remain unknown.

          Methods

          We conducted a multicentre pragmatic non-inferiority trial at three outpatient clinics in the Central Denmark Region. A total of 152 incident outpatients with CKD were randomised (1:1:1) to either PRO-based, PRO-telephone follow-up or standard of care (SoC). The primary outcome was the annual change in kidney function measured by the slope of the estimated glomerular filtration rate (eGFR). The non-inferiority margin was an eGFR of 2.85 ml/min/1.73 m 2/year. Mean differences were estimated using intention-to-treat (ITT), per protocol and random coefficient models.

          Results

          Mean eGFR slope differences between PRO-based and SoC were −0.97 ml/min/1.73 m 2/year [95% confidence interval (CI) −3.00–1.07] and −1.06 ml/min/1.73 m 2/year (95% CI −3.02–0.89) between PRO-telephone and SoC. Non-inferiority was only established in the per-protocol analysis due to CIs exceeding the margin in the ITT group. Both intervention groups had fewer outpatient visits: −4.95 (95% CI −5.82 to −4.08) for the PRO-based group and −5.21 (95% CI −5.95 to −4.46) for the PRO-telephone group. We found no significant differences in quality of life, illness perception or satisfaction.

          Conclusion

          Differences in the eGFR slope between groups were non-significant and results on non-inferiority were inconclusive. Thus, transitioning to remote PRO-based follow-up requires close monitoring of kidney function. Reducing patients’ attendance in the outpatient clinic was possible without decreasing either quality of life or illness perception.

          ClinicalTrials.gov identifier: NCT03847766

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

          Research electronic data capture (REDCap) is a novel workflow methodology and software solution designed for rapid development and deployment of electronic data capture tools to support clinical and translational research. We present: (1) a brief description of the REDCap metadata-driven software toolset; (2) detail concerning the capture and use of study-related metadata from scientific research teams; (3) measures of impact for REDCap; (4) details concerning a consortium network of domestic and international institutions collaborating on the project; and (5) strengths and limitations of the REDCap system. REDCap is currently supporting 286 translational research projects in a growing collaborative network including 27 active partner institutions.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            RoB 2: a revised tool for assessing risk of bias in randomised trials

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

              Summary Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. Methods The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function. Findings Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2·8%, −1·5 to 6·3). In 2017, 697·5 million (95% UI 649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence remained stable (1·2%, −1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney function. Interpretation Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI. Funding Bill & Melinda Gates Foundation.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Kidney J
                Clin Kidney J
                ckj
                Clinical Kidney Journal
                Oxford University Press
                2048-8505
                2048-8513
                July 2024
                14 June 2024
                14 June 2024
                : 17
                : 7
                : sfae176
                Affiliations
                AmbuFlex – Centre for Patient-reported Outcomes, Gødstrup Hospital , Herning, Denmark
                Department of Clinical Medicine, Aarhus University , Aarhus, Denmark
                AmbuFlex – Centre for Patient-reported Outcomes, Gødstrup Hospital , Herning, Denmark
                Department of Renal Medicine, Gødstrup Hospital , Herning, Denmark
                Department of Internal Medicine, Viborg Regional Hospital , Viborg, Denmark
                AmbuFlex – Centre for Patient-reported Outcomes, Gødstrup Hospital , Herning, Denmark
                Department of Clinical Medicine, Aarhus University , Aarhus, Denmark
                Department of Clinical Epidemiology, Aarhus University Hospital , Aarhus, Denmark
                Department of Clinical Medicine, Aarhus University , Aarhus, Denmark
                Department of Renal Medicine, Aarhus University Hospital , Aarhus, Denmark
                Department of Clinical Medicine, Aarhus University , Aarhus, Denmark
                Department of Rheumatology, Aarhus University Hospital , Aarhus, Denmark
                Author notes
                Correspondence to: Birgith Engelst Grove; E-mail: bigcri@ 123456rm.dk

                These authors share last authorship.

                Author information
                https://orcid.org/0000-0002-3763-9911
                https://orcid.org/0000-0002-5830-5814
                https://orcid.org/0000-0003-0103-4328
                Article
                sfae176
                10.1093/ckj/sfae176
                11240050
                f3dd3fd5-0f85-4c89-ad48-89da1dc89f7a
                © The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@ 123456oup.com

                History
                : 27 September 2023
                : 12 July 2024
                Page count
                Pages: 11
                Funding
                Funded by: Karen Elise Jensen Foundation, DOI 10.13039/501100004046;
                Categories
                Original Article
                AcademicSubjects/MED00340

                Nephrology
                chronic kidney disease,outpatient care,patient-reported outcome measures,randomized controlled trial,remote symptom monitoring

                Comments

                Comment on this article